Form 4: Gilead Sciences CEO Daniel O'Day Reports Stock Transactions
SEC Form 4 Filing
Gilead Sciences CEO Daniel O'Day reports the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.
Summary
- On September 10, 2024, Daniel O'Day, the Chairman and CEO of Gilead Sciences, Inc., reported transactions involving the company's common stock.
- Specifically, 10,295 restricted stock units vested, converting into an equal number of common shares.
- Following the vesting, O'Day sold 4,749 shares at a price of $81.44 per share to satisfy tax withholding obligations.
- After these transactions, O'Day directly owns 495,995 shares of Gilead Sciences common stock and 115,272 restricted stock units.
Sentiment
Score: 5
Explanation: This is a neutral disclosure of stock transactions, with no inherent positive or negative sentiment.
Industry Context
This filing is a routine disclosure of stock transactions by a company executive, which is common practice for publicly traded companies. It provides transparency into the executive's holdings and transactions in the company's stock.
Stakeholder Impact
- The transactions have a minimal direct impact on stakeholders, as they represent routine stock activity by a company executive.
Key Dates
| Date | Description |
|---|---|
| 09/10/2024 | Date of stock transactions (vesting of restricted stock units and sale of shares). |
| 09/11/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.